Dihydro-β-erythroidine hydrobromide_product_DataBase

Bioactivity	Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities[1][2][3].
In Vivo	Dihydro-Beta-Erythroidine hydrobromide (DHβE hydrobromide; 10 nmol/0.5 μL) is infused into the respective areas prior to a systemic nicotine injection (0.2 mg/kg; SC). DHβE infused into the ventral tegmental area (VTA), nucleus accumbens (NAcc), or infralimbic (IL) cortex, but not prelimbic (PrL) cortex, attenuated nicotine-enhanced responding for a conditioned reinforcer (CRf)[2].The co-administration of Dihydro-Beta-Erythroidine hydrobromide (5.0 mg/kg; s.c) with nicotine (0.2 and 0.4 mg/kg; s.c.) prevents the development of conditioned taste aversions (CTAs)[4]. Animal Model:
Name	Dihydro-β-erythroidine hydrobromide
CAS	29734-68-7
Formula	C16H22BrNO3
Molar Mass	356.25
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Harvey SC, et al. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996 Nov;67(5):1953-9. [2]. Tabbara RI, et al. Nicotine enhances responding for conditioned reinforcement via α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, but not the nucleus accumbens or the prefrontal cortex. Neuropharmacology. 2019 Apr;148:68-76. [3]. Clementson S, et al. Enantioselective Total Synthesis of (+)-Dihydro-β-erythroidine. J Am Chem Soc. 2019 Jun 5;141(22):8783-8786.

PeptideDB

Dihydro-β-erythroidine hydrobromide

CAS: 29734-68-7 F: C16H22BrNO3 W: 356.25